POEWE, Werner, Pierre BURBAUD, Giovanni CASTELNOVO, Wolfgang H. JOST, Andres O. CEBALLOS-BAUMANN, Marta BANACH, Anna POTULSKA-CHROMIK, Joaquim J. FERREIRA, Katalin BIHARI, Edvard EHLER, Martin BAREŠ, Lyudmyla A. DZYAK, Anna N. BELOVA, Emmanuel PHAM, Wenzhong Jerry LIU and Philippe PICAUT. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. Movement Disorders. Hoboken: Wiley-Blackwell, 2016, vol. 31, No 11, p. 1649-1657. ISSN 0885-3185. Available from: https://dx.doi.org/10.1002/mds.26760.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial
Authors POEWE, Werner (40 Austria), Pierre BURBAUD (250 France), Giovanni CASTELNOVO (250 France), Wolfgang H. JOST (276 Germany), Andres O. CEBALLOS-BAUMANN (276 Germany), Marta BANACH (616 Poland), Anna POTULSKA-CHROMIK (616 Poland), Joaquim J. FERREIRA (620 Portugal), Katalin BIHARI (348 Hungary), Edvard EHLER (203 Czech Republic), Martin BAREŠ (203 Czech Republic, guarantor, belonging to the institution), Lyudmyla A. DZYAK (804 Ukraine), Anna N. BELOVA (643 Russian Federation), Emmanuel PHAM (250 France), Wenzhong Jerry LIU (840 United States of America) and Philippe PICAUT (643 Russian Federation).
Edition Movement Disorders, Hoboken, Wiley-Blackwell, 2016, 0885-3185.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 7.072
RIV identification code RIV/00216224:14110/16:00092396
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/mds.26760
UT WoS 000387415700012
Keywords in English abobotulinumtoxinA solution for injection; cervical dystonia; Toronto Western Spasmodic Torticollis Rating Scale
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 18/12/2016 15:27.
Abstract
Background Approved botulinum toxin A products require reconstitution. AbobotulinumtoxinA solution for injection is a ready-to-use liquid formulation of abobotulinumtoxinA. Objectives The objective of this study was to demonstrate the superior efficacy of abobotulinumtoxinA solution for injection to placebo and to test the noninferior efficacy of abobotulinumtoxinA solution for injection versus abobotulinumtoxinA (dry formulation) in cervical dystonia. Methods This was a phase-3, multicenter, prospective, double-blind, randomized, active, and placebo-controlled study (N=369). Patients with cervical dystonia were randomized (3:3:1) to abobotulinumtoxinA solution for injection 500 U, abobotulinumtoxinA 500 U, or placebo. Following the double-blind phase, patients received abobotulinumtoxinA solution for injection, open-label, for up to 4 cycles. The primary outcome was change from baseline at week 4 of the Toronto Western Spasmodic Torticollis Rating Scale total score. Secondary measures included change from baseline or cycle baseline in Toronto Western Spasmodic Torticollis Rating Scale scores. Results At week 4, both products were superior to placebo (Toronto Western Spasmodic Torticollis Rating Scale total score least square mean decrease from baseline, abobotulinumtoxinA solution for injection 500 U -12.5, abobotulinumtoxinA 500 U -14.0, placebo -3.9; P<.0001 vs placebo). The noninferiority limit of 3 points in the Toronto Western Spasmodic Torticollis Rating Scale total score at week 4 was not met for abobotulinumtoxinA solution for injection versus abobotulinumtoxinA. Toronto Western Spasmodic Torticollis Rating Scale total score reductions were maintained for up to 4 cycles of abobotulinumtoxinA solution for injection open-label follow-up treatment. Safety profiles of abobotulinumtoxinA solution for injection and abobotulinumtoxinA were similar, with dysphagia and injection-site pain the most frequent drug-related adverse events. Conclusions Although the predefined noninferiority criterion was not met, abobotulinumtoxinA solution for injection was similarly effective to freeze-dried abobotulinumtoxinA in reducing Toronto Western Spasmodic Torticollis Rating Scale total scores with a similar safety profile. AbobotulinumtoxinA solution for injection efficacy was maintained with chronic open-label treatment, and this novel formulation may add convenience as well as dosing accuracy to treatment with abobotulinumtoxinA.
PrintDisplayed: 22/5/2024 08:09